Copy to clipboard 
Regenexx published its randomized controlled trial (RCT) mid-term results showing primary anterior cruciate ligament (ACL) healing without the need for invasive surgery. This was achieved through precise, image-guided injections of autologous bone marrow concentrate and platelets in patients failing conservative care. The goal of the study was to determine whether ACL tears could be treated through injections and how that compares to exercise therapy. Key indicators such as pain and function levels were studied at various time points over 24 months.
Dr. Chris Centeno, Regenexx’s Chief Medical Officer, explains that “having RCT data showing that we can help ACL tear patients avoid invasive surgery and retain their native ACL is a game changer.” Typically, in ACL surgery the natural ligament is torn out and replaced with a new graft tendon taken from the patient or from a deceased donor. In addition to retaining the natural integrity of the knee, by preserving their native ACL through Regenexx’s Perc-ACLR injection-based procedure, patients may reduce their risk for developing arthritis and decrease cartilage loss in the future. Further, avoiding surgery means less procedural risk, less down-time, and a quicker return to activity.
Versus exercise therapy, the mid-term results of high-dose bone marrow concentrate and injections into the ACL showed significant and lasting improvement (vs. baseline) in the key functional and pain indicators. Patients showed improved functionality as early as three months into the study and improved pain at month six. Both function and pain continued to improve through the entirety of the 24-month study. Comparatively, those patients randomized into the exercise therapy group showed no significant improvement in pain or function at any of the intervals over 24 months.
Source: Regenexx
Regenexx published its randomized controlled trial (RCT) mid-term results showing primary anterior cruciate ligament (ACL) healing without the need for invasive surgery. This was achieved through precise, image-guided injections of autologous bone marrow concentrate and platelets in patients failing conservative care. The goal of the study was to...
Regenexx published its randomized controlled trial (RCT) mid-term results showing primary anterior cruciate ligament (ACL) healing without the need for invasive surgery. This was achieved through precise, image-guided injections of autologous bone marrow concentrate and platelets in patients failing conservative care. The goal of the study was to determine whether ACL tears could be treated through injections and how that compares to exercise therapy. Key indicators such as pain and function levels were studied at various time points over 24 months.
Dr. Chris Centeno, Regenexx’s Chief Medical Officer, explains that “having RCT data showing that we can help ACL tear patients avoid invasive surgery and retain their native ACL is a game changer.” Typically, in ACL surgery the natural ligament is torn out and replaced with a new graft tendon taken from the patient or from a deceased donor. In addition to retaining the natural integrity of the knee, by preserving their native ACL through Regenexx’s Perc-ACLR injection-based procedure, patients may reduce their risk for developing arthritis and decrease cartilage loss in the future. Further, avoiding surgery means less procedural risk, less down-time, and a quicker return to activity.
Versus exercise therapy, the mid-term results of high-dose bone marrow concentrate and injections into the ACL showed significant and lasting improvement (vs. baseline) in the key functional and pain indicators. Patients showed improved functionality as early as three months into the study and improved pain at month six. Both function and pain continued to improve through the entirety of the 24-month study. Comparatively, those patients randomized into the exercise therapy group showed no significant improvement in pain or function at any of the intervals over 24 months.
Source: Regenexx
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
